Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Accumulated Expenses (2020 - 2025)

Xeris Biopharma Holdings' Other Accumulated Expenses history spans 6 years, with the latest figure at $43.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 3871.81% year-over-year to $43.3 million, compared with a TTM value of $43.3 million through Dec 2025, up 3871.81%, and an annual FY2025 reading of $43.3 million, up 3871.81% over the prior year.
  • Other Accumulated Expenses for Q4 2025 was $43.3 million at Xeris Biopharma Holdings, up from $2.6 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $43.3 million in Q4 2025, with the low at $337000.0 in Q3 2022.
  • Average Other Accumulated Expenses over 5 years is $11.1 million, with a median of $4.7 million recorded in 2021.
  • Year-over-year, Other Accumulated Expenses plummeted 95.03% in 2022 and then soared 3871.81% in 2025.
  • Tracing XERS's Other Accumulated Expenses over 5 years: stood at $2.0 million in 2021, then soared by 746.4% to $16.8 million in 2022, then plummeted by 93.06% to $1.2 million in 2023, then dropped by 6.68% to $1.1 million in 2024, then soared by 3871.81% to $43.3 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Other Accumulated Expenses are $43.3 million (Q4 2025), $2.6 million (Q3 2025), and $1.6 million (Q2 2025).